Background: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical riskbased approach on treatment for patients with diabetes.
Background
Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society [1] , important studies have been published in the area of cardiovascular assessment and prevention in patients with diabetes [2] . These studies have deeply advanced the current view on primary and secondary prevention in diabetes, and suggested new approaches on cardiovascular risk stratification, new cholesterol-lowering drugs, and new anti-hyperglycemic drugs with novel significant cardiovascular effects and mortality reduction.
To address this challenge, and in recognition of the multifaceted nature of disease, the Brazilian Diabetes Society joined the Brazilian Society of Cardiology and the Brazilian Endocrinology and Metabolism Society and gathered an expert panel formed by 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date evidence-based guidelines with practical recommendations on both the stratification and prevention of cardiovascular disease in diabetes. The main innovations include: (1) considerations on the impact of new anti-hyperglycemic drugs and new lipid-lowering drugs on cardiovascular risk; (2) a practical risk factor-based approach to guide statin use, including new definitions of LDLcholesterol and non-HDL-cholesterol targets; (3) an evidence-based approach to evaluate silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) the best current approaches for treating hypertension; and (5) recommendation updates for the use of antiplatelet therapy. We hope these guidelines will help clinicians to improve the quality of the care provided to patients with diabetes.
Methods
Initially, the panel members were divided into seven subcommittees to define the main topics requiring an updated position from the societies. Panel members searched PUB-MED for randomized clinical trials and meta-analyses of clinical trials, and observational studies of good quality published from 1997 to 2017 using MeSH terms: [ . Low quality observational studies, meta-analyses with high heterogeneity and cross-sectional studies were not included although they might have influenced the level of evidence indicated. Expert opinion was used when the results of the search were not satisfactory for a specific item. It is important to note that it was not the aim of this position statement to include a rigorous systematic review.
A preliminary manuscript outlining recommendation grades and levels of evidence (Table 1) was then drafted. This step took several rounds of discussion among subcommittee members, who reviewed the findings and made new suggestions. The manuscript was and CLAD (Table 5) are not present in these risk groups. As seen in a large Ontario population-based retrospective cohort study, 379,003 individuals with diabetes were included and followed up for a mean of 8 years until the occurrence of a first acute myocardial infarction or death from all causes [3] . The transition from LOW to INTERMEDIATE RISK occurred at ages 38 and 46 years respectively for men and women. The transition from INTERMEDIATE to HIGH-RISK status occurred (Table 3) b Subclinical atherosclerosis (Table 4) c Clinical atherosclerotic disease (Table 5 )
Table 3 Stratifying risk factors (SF)
a Valid for patients in whom the onset of diabetes occurred after 18 years of age b Family history of premature coronary heart disease is defined as the presence of coronary events in first-degree relatives (father, mother, or siblings) when occurring before 55 years of age in men or before 65 years of age in women c The IDF definition of Metabolic Syndrome consists of: (1) abdominal circumference >90 cm for men and >80 cm for women, plus; (2) triglycerides >150 mg/dL for both men and women; (3) HDL-c < 40 mg/dL in men and <50 mg/dL in women; (4) blood pressure ≥130/85 mmHg or treatment for hypertension; and (5) a fasting blood glucose ≥100 mg/dL d Current smoking is defined when the last smoking episode occurred less than 1 year before the time of stratification Age >49 years in men or >56 years in women [3] Duration of diabetes greater than 10 years [4] a Family history of premature coronary heart disease [5] b
Presence of IDF-defined Metabolic Syndrome [6] c Treated or untreated hypertension [7] Bertoluci et al. Diabetol Metab Syndr (2017) 9:53 respectively at ages: 49 and 56, for both men and women [3] . Therefore, patients with diabetes without clinical or subclinical cardiovascular disease and risk factors are considered at INTERMEDIATE RISK when aged are 38-49 years (men) or 46-56 years (women), and at LOW RISK if they are younger. The HIGH-RISK group is defined by the presence, at any age, of at least one SF (Table 3) or one indicator of SCAT (Table 4) , in the absence of CLAD (Table 5) . Even in the absence of these conditions, a patient with diabetes is also considered at HIGH RISK when age is above 49 years in men or 56 years in women. Finally, the VERY HIGH-RISK group includes patients who, at any age, have CLAD as defined in Table 5 .
Module 2: Screening of subclinical atherosclerosis

Coronary artery calcification (CAC) score is associated with cardiovascular events and mortality in patients with diabetes [I, A]
Summary of evidence
• Coronary artery calcification (CAC) is a marker for the presence and burden of atherosclerosis, as demonstrated in anatomical studies [22] . The MESA [23] and Heinz Nixdorf [24] studies demonstrated that CAC is a predictor of coronary events and is useful for stratification of cardiovascular risk among patients in primary prevention. This is also true for patients with diabetes: the higher the CAC score, the higher the risk of cardiovascular events in subjects with diabetes [25] .
• Raggi et al. [26] followed 10,377 asymptomatic individuals (903 with diabetes), who had been investigated with CAC at baseline, for a mean of 5 years. The mean CAC score was higher in patients with diabetes than in patients without diabetes (281 ± 567 vs. 119 ± 341, p < 0.0001). This study also showed that a higher CAC score was associated with a higher mortality rate, especially in patients with diabetes. However, the survival rate was similar to that observed in patients with and without diabetes (98.8% vs. 99 .4% respectively, p = 0.5) when CAC was zero.
• The PREDICT study [27] followed 589 patients with diabetes without cardiovascular disease (mean age 63.1 years) for a median of 4 years. The greater the coronary calcium score, the greater the risk of cardiovascular outcomes. The area under the ROC curve (AUC-ROC) for risk determination using the UKPDS risk score was 0.63, and was increased to 0.73 when CAC was included (p = 0.03).
Coronary artery calcium score (CAC score) determination has the best net reclassification rate compared to other risk markers when added to clinical global risk score calculators alone. This can be especially useful to reclassify patients at INTERMEDIATE risk to higher or lower-risk categories. However, this Panel recognizes that, despite its utility, CAC score may not be easy to obtain in a large proportion of patients [IIa, B]
Summary of evidence
• In a large cohort study of 44,052 asymptomatic individuals referred for CAC testing, including 2384 with diabetes [28] , the authors showed that cardiovascular risk was more accurately stratified with CAC in patients with diabetes. Patients in the low and moderate risk categories had a mortality rate of 39.4 deaths/1000/year when CAC was above 100. Conversely, those classified in the clinical high-risk category with no calcium present (CAC = 0) had a 10-year mortality rate of 6.59 deaths/1000/year. In the lower-risk subgroup (<5% in 10 years), 18% had CAC > 100, while in the higher risk category (>20% in 10 years), 16% had CAC = 0. In other words, CAC was able to reclassify a considerable number of lowrisk patients into a high-risk category [27] . A CAC score >0 was present in 57.3% of patients in the lowrisk category and in 70.6% of those in intermediaterisk categories.
• The prospective, community-based coronary artery risk development in young adults (CARDIA) study [29] recruited 5115 participants aged 18-30 years, with CAC measured at 15, 20, and 25 years after recruitment. The main outcomes were incident coronary heart disease, including fatal and nonfatal myo- Carotid plaque (intima-media thickness >1.5 mm) [14] Computed tomography coronary angiography (CCTA) with a definite plaque [15] b Ankle-brachial index <0.9 [16] Abdominal aortic aneurysm (AAA) [17] [18] [19] [20] [21] c Severe atherosclerotic disease (stenosis >50%) in any vascular territory cardial infarction, acute coronary syndrome without myocardial infarction, coronary revascularization, or CHD death. The probability of developing CAC by age 32-56 was estimated using clinical risk factors measured 7 years apart between ages 18 and 38. Participants were followed up for 12.5 years, with 57 incident CHD events and 108 incident CVD events observed. After adjusting for risk factors and treatments, those with any CAC had a fivefold increase in CHD events (hazard ratio [HR] 5.0, 95% CI 2.8-8.7) and a threefold increase in CVD events (HR 3.0, 95% CI 1.9-4.7). Within CAC score strata of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and >100, the HRs for CHD were 2.6 (95% CI 1.0-5.7), 5.8 (95% CI 2.6-12.1), and 9.8 (95% CI 4.5-20.5), respectively. A CAC score ≥100 was associated with an incidence of 22.4 deaths per 100 participants in 12.5 years (HR 3.7, 95% CI 1.5-10.0). The presence of CAC among individuals aged 32-46 was associated with increased risk of fatal and nonfatal CHD during 12.5 years of follow-up. Thus, screening for CAC might be considered in individuals with risk factors in early adulthood to inform discussions about primary prevention.
• The MESA study was a prospective populationbased cohort that investigated the prevalence and progression of subclinical cardiovascular disease in persons without cardiovascular disease at baseline, including 6814 men and women aged 45-84 years and 9.8% with diabetes, to assess the predictive accuracy and improvement in reclassification gained by the addition of CAC score (among others) over the atherosclerotic cardiovascular risk estimator (ASCVD). The authors concluded that CAC score had a modestly improved discriminative ability over ASCVD. The Harrell's C statistic difference was significant (0.74 vs. 0.76, p = 0.04), and CAC score addition was the only marker that improved ASCVD risk score [30] .
3. In patients with diabetes, a CAC score >10 is an indicator of increased mortality and future cardiovascular events. It is recommended that patients with diabetes with a CAC score >10 should be considered as HIGH RISK. [I, A] Summary of evidence
• In a meta-analysis of eight studies including 6521 patients with diabetes [31] , with a mean follow up of 5.18 years, the relative risk of the composite outcome of all-cause mortality and/or cardiovascular events with CAC > 10 vs. CAC < 10 was 5.47 (95% CI 2.59-11.53, p < 0.001) [31] . Nevertheless, it should be noted that significant heterogeneity was detected across studies (I 2 = 82.4%, p < 0.001). CAC > 10 had a sensitivity of 94% and a specificity of 34% for the composite outcome. A higher CAC score entailed lower sensitivity and higher specificity. For example, when comparing CAC < 10 vs. CAC > 1000, sensitivity dropped to 90%, while specificity increased to 74%. For an individual with diabetes and CAC < 10, post-test probability for the composite outcome was 1.8%, representing a 6.8-fold decrease in the pretest probability of a CVD outcome. The study concluded that a CAC < 10 is helpful to detect lower-risk individuals in this population.
• The Diabetes Heart Study monitored cardiovascular mortality in 1051 patients with diabetes followed for 7.4 years. A positive association was observed between CAC and mortality in the model adjusted for age, sex, race, smoking, and LDL-C. Using the group score of 0-9 for CAC as a reference, the study found the following relative risks according to CAC severity: CAC 10 [35] . All patients were evaluated for carotid plaque burden score based on a novel 3-dimensional carotid ultrasound and CAC score at baseline, and followed up for a median of 2.7 years. The main study outcome was the presence of MACE defined as cardiovascular death, myocardial infarction, and ischemic stroke. The authors analyzed the carotid plaque burden (cPB) through the sum of the areas of carotid plaques as seen along both carotid arteries and their ramifications. cPB was analyzed in tertiles. After adjustments for risk factors, and compared with individuals without any cPB, hazard ratios (HR) for MACE at tertiles 1, 2, and 3 were 0. • The detection of ischemia in asymptomatic diabetics (DIAD) multicenter randomized trial evaluated whether detection of silent myocardial ischemia in asymptomatic patients with diabetes could reduce cardiovascular events. The participants were randomized to undergo routine screening for detection of silent ischemia using adenosine stress myocardial perfusion single-photon emission computed tomography (SPECT) or no screening. A total of 1123 asymptomatic diabetic patients were randomized. After a mean follow-up of 4.8 years, a non-significant reduction in the overall cardiac event rate was detected in the screened vs. unscreened group, with HR of 0.88 (95% CI 0.44-1.88) [39] .
• A prospective, multicenter randomized trial-do you need to assess myocardial ischemia in type-2 diabetes (DYNAMIT) study [40] -evaluated screening for silent myocardial ischemia using a bicycle exercise test or dipyridamole stress SPECT in 631 asymptomatic diabetic patients with no evidence of coronary artery disease. The study was discontinued prematurely because of difficulties in recruitment and a lower-than-expected event rate. There were no significant differences between the screening and usualcare groups for the main outcome (HR 1.00, 95% CI 0.59-1.71). A meta-analysis of the DYNAMIT and DIAD trials [39] produced similar results, with narrower confidence intervals for each endpoint.
• The BARDOT trial [41] was a prospective multicenter study evaluating the prevalence, progression, treatment, and outcome of silent coronary artery disease (CAD) in 400 asymptomatic patients with diabetes at high coronary risk, without history or symptoms of CAD. Patients underwent myocardial perfusion SPECT (MPS) at baseline and after 2 years [41] . Patients with normal MPS received usual care, while those with abnormal MPS received medical or combined invasive and medical management. An abnormal MPS was found in 22% of patients. Normal-MPS patients had a low rate of first manifestations of CAD compared with patients with abnormal MPS at baseline. Patients with normal MPS had 2-year rates of MACE, cardiac death, and of new ischemia or new scar of 2.9, 0.7, and 3.2% respectively. Patients with abnormal MPS had a sevenfold higher rate of progression to "overt CAD, " independent of therapy [41] . However, although the BAR-DOT trial results suggested screening and treating high-risk patients on the basis of MPS, it is important to note that only about 20% of patients with an abnormal MPS would be advised to receive antiischemic therapy. [49] demonstrated that achieving an HbA1c below 7% reduces microvascular complications in type 1 and type 2 diabetes. In subjects with type 1 diabetes, implementing intensive glycemic control targeting an HbA1c below 7% in the first 6 years of diabetes can promote a 57% reduction in nonfatal myocardial infarction, stroke, and death from cardiovascular disease on long-term follow-up (9 years), as seen in the DCCT/EDIC study [50, 51] . Similarly, in type 2 diabetes, intensive glycemic control decreases cardiovascular outcomes in the long term (after 10 years) when implemented in recently diagnosed patients [52] .
• Lower HbA1c targets were evaluated in three randomized clinical trials: action to control cardiovascular risk in diabetes (ACCORD) [53] , action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) [54] , and the veterans affairs diabetes trial (VADT) [55] ). These trials did not detect reduction in cardiovascular outcomes when intensive control (HbA1c < 6.5%) was implemented. The ADVANCE study (n = 11,140), ACCORD (n = 10,251), and VADT (n = 1791) evaluated patients with type 2 diabetes and previous cardiovascular disease or risk factors and diabetes (mean duration 8-11.5 years), assessing incidence of cardiovascular disease after intensive vs. conventional treatment. The final mean HbA1c was 6.5 vs. 7.3% (ADVANCE), 6.4 vs. 7.5% (ACCORD), and 6.9 vs. 8.4% (VADT). In the ACCORD trial, but not in the other studies, a 22% increase in all-cause mortality followed intensive treatment. • Tight glucose control may be harmful in many patients, particularly the elderly and those with other illnesses, especially cardiovascular diseases [56] .
Less stringent
Intensive glycemic control does not lead to improved microvascular outcomes for at least 8 years. Data from randomized controlled trials suggest that intensive glycemic control immediately increases the risk of severe hypoglycemia 1.5-to 3-fold [57] .
• Observational data from emergency admissions showed a consistent increase in severe hypoglycemia over one decade, especially in type 2 diabetes patients with lower HbA1c, more comedication, and more concomitant diseases [58, 59] . Hypoglycemia in these patients has been associated with increased mortality, higher risk of dementia, falls, fall-related fractures, cardiovascular events, and poor quality of life [60] . Mechanisms by which acute hypoglycemia may trigger ischemia, arrhythmia, and cardiovascular events include increases in epinephrine and norepinephrine levels, which may induce increased cardiac rate and/or contractility, thus heightening myocardial oxygen consumption, while also precipitating vasoconstriction and platelet aggregation. Moreover, acute hypoglycemia in the presence of hypokalemia prolongs cardiac repolarization and increases the QT interval, favoring a proarrhythmic state [60] .
• In patients with diabetes from a Brazilian multicenter registry followed for 12 months, failure to reach HbA1c targets was associated with poorer eventfree survival (all-cause mortality, nonfatal cardiac arrest, myocardial infarction, or stroke) as compared to good metabolic control (p < 0.041). In that study, HbA1c targets of 8.0 and 7.0% were considered in patients without a previous cardiovascular event vs. those with a previous cardiovascular event [61] .
• Patients with limited resources and a limited support system, those with lower motivation, non-adherent patients, and those with diminished self-care capacity are not candidates for strict glucose control, as the risk of hypoglycemia tends to be higher [62] .
• Considering the high risk of hypoglycemia with strict metabolic control, especially in elderly patients and in those in which this adverse effect may be more harmful, individualized targets should be pursued in patients with a known history of severe and frequent hypoglycemic events, longstanding disease, short life expectancy, major comorbidities, and established vascular complications [63] . Considering these data and the results of observational studies, the harms associated with an HbA1c target lower than 7.5% or higher than 9% are likely to outweigh the benefits in most adults older than 65 years [57, 64] .
• Data to guide this type of individualized treatment are derived from weak evidence. However, the high frequency of risk factors for hypoglycemia and its adverse impact, as well as the marginal benefits of tight control in individuals with short life expectancy, suggest a need to reduce overtreatment, particularly among the elderly and the other groups cited above [56, 60, 64] .
Hospitalized patients
14. In hospitalized patients with acute myocardial infarction, it is recommended that blood glucose be maintained in the 130-200 mg/dL range by continuous intravenous insulin infusion, followed by good long-term metabolic control. [I, B] Summary of evidence
• The DIGAMI [65] study included 620 patients with diabetes and acute myocardial infarction (AMI) and used the following strategies: IV infusion of insulin and glucose in the first 24 h with a glycemic target of 126-196 mg/dL, subcutaneous administration of insulin four times daily for 3 months, vs. standard insulin therapy as clinically indicated at the time of the study. Treatment with insulin in the acute phase produced better glycemic control during hospitalization, at 3 months and at 1 year, as well as lower mortality rates at 1 and 3.4 years of follow-up.
• In the DIGAMI-2 trial [66] , use of insulin during hospitalization and after discharge was compared to insulin therapy only during hospitalization and usual treatment throughout the period. Glycemic control and cardiovascular outcomes were similar in the two groups.
• In the HI-5 study [67] , 240 patients with diabetes and glucose ≥140 mg/dL were included at hospital admission for AMI and randomized to strict glycemic control (target glycemia 72-180 mg/dL) with insulin plus intravenous glucose infusion for at least 24 h or conventional therapy. After discharge, the patients were managed by their physician, with a recommendation to maintain HbA1c < 7%. The groups had similar in-hospital mortality rates.
In patients undergoing cardiac surgery, it is recommended that blood glucose be maintained in the 120-150 mg/dL range through continuous intravenous insulin infusion during the hospitalization period. [I, A]
Summary of evidence
• Hyperglycemia before or after cardiac surgery has been associated with increased risk of complications (death, prolonged mechanical ventilation, renal failure, stroke, and deep sternal infection) [68, 69] .
• The observational Portland Diabetes Project study evaluated the relationship between hyperglycemia and adverse outcomes of cardiac surgery in patients with diabetes. In the study, continuous intravenous insulin, adjusted by frequent blood glucose tests was used based on a standardized protocol conducted by nurses. Initial glucose target was 150-200 mg/dL. This was later changed to 125-175 mg/dL and then to 100-150 mg/dL because other studies were identifying the need to normalize blood glucose reduction outcomes. The use of this protocol vs. subcutaneous insulin according to glucose levels (historical control) was associated with reduced rates of infection [70] and death in about 50% of patients [71] .
• A randomized controlled trial with surgical intensive coronary unit patients (63% cardiac surgery and 13% diabetes) showed benefit of intensive glycemic control (insulin infusion glycemic target 80-110 mg/dL) vs. usual glycemic control (180-200 mg/dL) in mortality, infection, acute renal failure requiring hemodialysis, blood transfusion, and polyneuropathy in critically ill patients. However, intensive glycemic control was associated with higher rates of hypoglycemia [72] .
• Nevertheless, the multicenter NICE SUGAR Study, conducted in medical (63%) and surgical intensive coronary units (37% of patients respectively; 20% with a history of diabetes), showed that intensive glycemic control (target < 108 mg/dL) vs. usual control (140-180 mg/dL) increased mortality and hypoglycemia rates [73] . A meta-analysis including data from the NICE SUGAR study, with separate analysis of clinical and surgical ICUs, showed that tight glucose control did not reduce mortality in the clinical ICU, but may bring benefit to surgical patients when target blood glucose is <150 mg/dL [74] . A small RCT comparing two glycemic targets (90-120 mg/dL vs. 120-180 mg/dL) in patients with diabetes undergoing coronary artery bypass grafting showed increased risk of hypoglycemia and absence of benefit with more strict blood glucose control [75] .
A basal plus bolus correction insulin regimen (a strategy using multiple doses of long-and short-acting insulins) is a reasonable option for correcting hyperglycemia in hospitalized, non-critically ill diabetic patients. [IIa, B] The use of sliding-scale insulin in the inpatient hospital setting is discouraged. [III, C]
Summary of evidence
• Hyperglycemia in in-hospital patients with diabetes is very common. Retrospective and randomized controlled trials in surgical populations have reported that hyperglycemia of diabetes is associated with increased length of stay, hospital complications, resource utilization, and mortality [76, 77] .
• A randomized controlled trial showed that basalbolus treatment (glargine and glulisine) improved glycemic control and reduced hospital complications (wound infection, pneumonia, acute renal failure, and bacteremia) compared with sliding-scale insulin (glulisine) in general surgery patients with type 2 diabetes [78] .
• Some RCTs were performed in type 2 diabetic patients hospitalized for nonsurgical conditions. In this population, basal-bolus treatment (glargine and glulisine or NPH and regular) also improved glycemic control compared with sliding-scale insulin [79, 80] .
Outpatient treatment: monotherapy
In patients with recently diagnosed type 2 diabetes, metformin plus non-pharmacological therapy including physical activity and targeted nutrition therapy for weight control is recommended as first-line therapy. [I, A]
Summary of evidence
• Metformin has a favorable efficacy and safety profile, with important metabolic effects and cardiovascular benefits. Due to its effect in reducing cardiovascular events and mortality, its efficacy in blood glucose reduction with low incidence of hypoglycemia, low cost, tolerable adverse effects, and no association with weight gain, it is the current first-line agent of choice for treatment of hyperglycemia in type 2 diabetes [81] . Titration or addition of further hypoglycemic drugs should be implemented as soon as possible to avoid inertia in achieving glucose targets.
In patients who do not tolerate metformin, any other antidiabetic drug can be recommended as monotherapy, except if contraindicated. [I, C]
Summary of evidence
• The UKPDS analyzed 5102 recently diagnosed type 2 diabetes patients followed up from 1977 to 1997 and found that intensive glycemic control with sulfonylurea or insulin therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks. In obese patients, the UKPDS showed that metformin has similar efficacy to sulfonylureas for glucose control [52, 82, 83] .
• UKPDS 34 investigated whether intensive glucose control with metformin has any specific advantage or disadvantage. A subgroup analysis compared 411 recently diagnosed overweight (>120% ideal bodyweight) type 2 diabetes patients treated with diet alone versus 342 patients using metformin, aiming for a fasting plasma glucose <110 mg/dL, and found a relative risk reduction (RRR) of 32% (p = 0.002) of any diabetes-related complications, a 42% RRR for any death related to diabetes (p = 0.017), and a 36% RRR for all-cause mortality (p = 0.011). Table 6 Outpatient treatment: second agent 20. In an asymptomatic patient with recently diagnosed type 2 diabetes and HbA1c > 8.5%, combined pharmacological treatment for hyperglycemia consisting of metformin plus a second antihyperglycemic agent should be considered as first-line therapy. [IIa, C]
In patients with renal impairment, possible substitutions of anti-hyperglycemic drugs for type 2 diabetes are indicated in
Summary of evidence
• This is an expert opinion-based recommendation, not based on published evidence. The majority of members from the Panel recommends to start combined therapy with metformin above HbA1c > 8.5% to avoid delaying the attainment of optimal glycemic control; all efforts should be made to prevent severe hyperglycemia in treatment-näive patients with type 2 diabetes. • A meta-analysis of 18 RCTs (n-4535) evaluated the comparative efficacy of GLP-1 agonists, DPP-4 inhibitors, thiazolidinediones, and α-glucosidase inhibitors in reducing HbA1c, body weight, and causing severe hypoglycemia when a third drug was added to a metformin plus sulfonylurea regimen [86] . Despite limitations, as most of the studies were of short duration, with variable quality, and based on indirect comparisons, the meta-analysis showed that all antidiabetic classes were associated with significant reductions in HbA1c levels compared to placebo. The overall average reduction in Hba1c was −0.96% (thiazolidinediones, −1.15%; acarbose, −0.6%; GLP-1 agonists, −1.04%; DPP-4 inhibitors, −0.89%). There was no clear difference in efficacy between drug classes when adding a third agent to treatment of patients with type 2 diabetes who were already receiving metformin and a sulfonylurea [86] . • The UKPDS [52] and ORIGIN [87] are randomized controlled trials that used human insulin and the insulin analogue glargine, respectively, in type 2 diabetes and evaluated long-term cardiovascular outcomes. The UKPDS revealed a 15% reduction in myocardial infarction and a 13% reduction in death among people with new-onset type 2 diabetes treated intensively with antidiabetic agents and insulin, as needed to attain an HbA1c of 7.0% vs. usual care. The mean follow up was of 10 years [52] .
Insulin therapy (with
• In the ORIGIN study [87] , participants were randomly assigned to insulin glargine added as an evening injection to their preexisting anti-hyperglycemic regimen or to standard care (treatment according to the investigator's discretion in alignment with local guidelines). The study included 12,537 people, 88% of whom with type 2 diabetes, of which 59% had a previous cardiovascular event. After a mean follow up of 6.2 years, no differences were found between groups concerning the composite endpoint of nonfatal myocardial infarction, non-fatal stroke or cardiovascular death. These data indicate that basal insulin treatment (human insulin or insulin analogues) is safe in individuals with type 2 diabetes with or without pre-existing cardiovascular events.
• In the DEVOTE study (Efficacy and Safety of degludec versus glargine in type 2 diabetes), 7637 patients with type 2 DM were randomized to receive either insulin degludec or insulin glargine U100. The primary outcome (nonfatal myocardial infarction, nonfatal stroke and cardiovascular death) occurred in 8.5% of the patients treated with degludec and in 9.3% of the patients treated with glargine (hazard ratio = 0.91; p = non-significant). Patients treated with degludec experienced significant lower rates of severe hypoglycemia in comparison to the glargine U100 group (p < 0.001) [88] . ; p = 0.02; RRR −15%). There was no reduction in the incidence of nonfatal AMI, nonfatal stroke, or hospitalization for heart failure [91] .
• The SUSTAIN-6 trial analyzed 3297 patients with longstanding type 2 diabetes (mean disease duration 13.9 years) and established cardiovascular disease, chronic kidney disease, or both, on a standard care regimen, who were randomly assigned to receive once-weekly semaglutide (0.5 or 1.0 mg) or placebo for 104 weeks. At 2-year follow-up, there was a 26% reduction in the composite primary outcome or CV mortality, nonfatal AMI, and nonfatal stroke (6.6% vs. 8.9%, p = 0.02) [92] . Cardiovascular death was similar in the two groups (p = 0.92). Nonfatal stroke was the main composite primary outcome driver ( • A pre-specified subgroup analysis of the treat to new targets (TNT) study [104] , which included 1501 patients with diabetes and coronary artery disease, compared the impact of atorvastatin 80 mg vs. 10 mg on cardiovascular outcomes during 4.9 years. The study showed a significant reduction in any cardiovascular event and stroke in the 80 mg arm. The lower LDL-c attained with the highest dose showed additional benefit. [100] studied 18,144 patients who had been hospitalized for acute coronary syndrome within the preceding 10 days and had LDL-c levels of 50-100 mg/ dL while on lipid-lowering therapy or 50-125 mg/ dL if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo. The primary outcome was the composite of cardiovascular death, nonfatal myocardial infarction and unstable angina requiring re-hospitalization, coronary revascularization, or nonfatal stroke. The median follow-up was 6 years. The median timeweighted mean LDL-c level during the study was 53.7 mg/dL in the simvastatin-ezetimibe group, as compared with 69.5 mg/dL in the simvastatin alone group (p < 0.001). The event rate for the primary endpoint at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-alone group, with an absolute risk difference of 2.0% (HR 0.936, 95% CI 0.89-0.99, p = 0.016). Thus, vigorous reduction of LDL-c in the early phases of acute coronary syndrome resulted in improved cardiovascular outcomes and should be recommended. In addition, subgroup analysis revealed the greatest benefit in patients with diabetes, with a 15% reduction in the primary endpoint and a NNT = 18 [100] .
In patients with diabetes at HIGH RISK (Tables 2, 3, 4), LDL-c should be maintained below 70 mg/dL and/or non-HDL-c below 100 mg/dL. [I, A]
Alternatively, in HIGH-RISK diabetic patients not using statins, an initial reduction of >50% in LDL-c or in non-HDL-c is recommended. If, after 3 months, targets are not met (LDL-c < 70 mg/dL or non-HDL-c < 100 mg/dL), treatment should be intensified. [I, C]
Summary of evidence
• The Collaborative Atorvastatin Diabetes Study (CARDS) [115] , which was terminated early for efficacy, assessed 2838 patients with diabetes without coronary artery disease (age 40-75 years) and at least 1 additional risk factor (microalbuminuria, retinopathy, hypertension, or smoking). Patients were randomized to atorvastatin 10 mg or placebo during a mean follow-up of 3.9 years, a composite of acute coronary events, coronary revascularization, or stroke as primary outcome. Atorvastatin 10 mg was associated with risk reduction of 37% (95% CI −52 to −17, p = 0.001) in the primary endpoint, reduction of 32% (95% CI −45 to −15, p = 0.001) in stroke risk, and a trend toward 27% reduction in total mortality (95% CI −48 to 1.0, p = 0.059). The CARDS estimated that one event is avoided for every 27 patients treated for 4 years.
• In the MRC/BHF Heart Protection Study (HPS)
substudy [116] , 5963 individuals with diabetes (age 40-80 years) were randomized to simvastatin 40 mg or placebo. A pre-specified subgroup analysis was performed for the outcomes of fatal and nonfatal acute myocardial infarction (AMI) and first vascular event (major coronary event, stroke, or revascularization). Simvastatin 40 mg reduced these outcomes by 33% (95% CI 17-46, p < 0.0003), regardless of baseline LDL-c level. The absolute reduction of cardiovascular disease risk in patients with diabetes without coronary artery disease was similar for the HPS and the CARDS studies. This confirms the benefit of statins for primary prevention in high-risk patients with diabetes.
• In the pre-specified subgroup analysis of the treat to new targets (TNT) study [104] , with 1501 patients with diabetes and coronary artery disease, intensive treatment with atorvastatin 80 mg was associated with a significant reduction in any cardiovascular events and stroke compared with atorvastatin 10 mg in a 4.9-year follow-up. Patients taking 10 mg achieved an average level of LDL-c of 96 mg/dL, while those using 80 mg/day achieved 77 mg/dL. Thus, the attainment of a target LDL-c below 70 mg/ dL showed additional benefit. • A systematic search and meta-analysis including 11 trials was performed to evaluate the impact of statin therapy on carotid intima media thickening (CIMT) progression. Statin therapy was found to slow the progression of carotid atherosclerosis, indicating benefits at the subclinical stage of the disease process [117] . 
In patients with diabetes at HIGH RISK, with either stratifying factors (
In patients with diabetes at LOW-INTERMEDIATE RISK, LDL-c levels should be lowered and maintained below 100 mg/dL and non-HDL-c levels should be lowered and maintained below 130 mg/dL (Table 7). [I, B]
Summary of evidence
• In a meta-analysis of 14 trials including 18,686 individuals with diabetes, statin therapy reduced allcause mortality and vascular mortality, and the reduction in vascular events was proportional to the LDL-c reduction. The proportional effects of statins in diabetic patients were similar irrespective of prior history of vascular disease or other baseline clinical conditions [101] . (Table 9) , if LDL-c and non-HDL-c are above the targets (Table 7) . Lipid profile should be re-checked periodically to ensure that LDL-c level is below 100 mg/ dL.
Statins are initially optional for LOW RISK patients, but should be considered in INTERMEDIATE RISK patients
Intensification of treatment is needed if targets are not met. [IIa, C]
Summary of evidence
• The TRIALIST meta-analysis [118] compared the effects of lowering cholesterol with statins on the incidence of cardiovascular events in a low-risk population. The meta-analysis included 22 statin vs. control trials (n = 134,537) with mean follow-up duration of 4.8 years, and five more vs. less statin trials (n = 39,612) with 5.1 years of follow-up. Participants were separated into five categories of baseline 5-year major vascular event risk on control therapy (<5, ≥5 to <10, ≥10 to <20, ≥20 to <30, ≥30%), with estimation of the rate ratio (RR) per 1.0-mmol/L LDL-c reduction in each category. Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0.79, 95% CI 0.77-0.81, per 1.0 mmol/L reduction), irrespective of age, sex, baseline LDL-c, or previous vascular disease, and of vascular and allcause mortality. The proportional reduction in major vascular events was at least as great in the two lowest risk categories as in the higher risk categories. This reflected significant reductions in major coronary events in the two lowest risk categories. In individuals with 5-year risk of major vascular events <10%, each 1-mmol/L reduction in LDL-c produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. These data indicate that low-risk populations also benefit from lowering cholesterol with statins.
It is recommended that patients with diabetes and LDL-c > 190 mg/dL be investigated for familiar hypercholesterolemia (FH). [I, C]
Summary of evidence
• The diagnosis of FH in patients with diabetes should be always considered and further investigated when an LDL-c level > 190 mg/dL is found [106] . LDL-c > 250 mg/dL in a patient aged 30 or older, LDL-c > 220 mg/dL in patients aged 20-29, and LDL-c > 190 mg/dL in patients under age 20 yields approximately 80% probability of FH in the setting of general population screening [107] . • In the 4D (die deutsche diabetes dialyze) study [119] , 1255 patients with type 2 diabetes on hemodialysis were evaluated. They were randomized to atorvastatin 20 mg or placebo and followed up for 4 years. The primary endpoint was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. A 42% reduction in LDL-c was observed in patients on atorvastatin, with no reduction in the primary outcome. The risk of stroke was also increased in this group.
It is recommended that patients with diabetes and chronic kidney failure who are on dialysis, without CLAD (
• The study to evaluate the use of rosuvastatin in subjects on regular hemodialysis (AURORA) study [120] included 2776 hemodialysis patients (aged 50-80, 27.9% with diabetes) treated with rosuvastatin 10 mg/day or placebo during a mean of 3.8 years. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. There was a 43% reduction in LDL-c in the intervention group, but no differences in the primary outcome were observed between groups.
• Regarding patients with chronic renal disease but not on hemodialysis, the Pravastatin Pooling Project database made a combined analysis of results of three randomized trials of pravastatin 40 mg vs. placebo [121] ). Significant benefit of treatment was detected in reducing the primary endpoint of myocardial infarction, coronary death, or percutaneous revascularization and total mortality in this group of patients.
• The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in people with moderate-to-severe kidney disease. This randomized, double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247 not on dialysis) with no known history of myocardial infarction or coronary revascularization. Patients were randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo. The key pre-specified outcome was first major atherosclerotic event (nonfatal myocardial infarction or coronary death, nonhemorrhagic stroke, or any arterial revascularization procedure). All analyses were by intention to treat. A total of 4650 patients were assigned to receive simvastatin plus ezetimibe, and 4620 to placebo. Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference of 33 mg/dL (SE 0.02, with about two-thirds of the sample adherent) during a median follow-up of 4.9 years, and produced a 17% proportional reduction in major atherosclerotic events (526 [ . Adjustment for subgroup-specific reductions in LDL-c did not reveal evidence of differences between the proportional effects on major atherosclerotic events and the summary rate ratio in any subgroup examined, and, in particular, in patients on dialysis vs. those who were not on dialysis. The study concluded that reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in patients with advanced chronic kidney disease [122] .
• A sub-analysis of the treating to new targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease. A total of 10,001 patients with coronary heart dis- ease and LDL-c levels < 130 mg/dL were randomly assigned to double-blind therapy with 10 or 80 mg/d atorvastatin. Estimated GFR using the modification of diet in renal disease equation was compared at baseline and at the end of follow-up in 9656 participants with complete renal data. The expected 5-year decline in renal function was not observed. However, estimated GFR improved in both treatment groups, but was significantly greater with 80 mg than with 10 mg, suggesting this benefit may be dosage-related [123] .
• Another sub-analysis of the TNT study investigated the effects of intensive lipid lowering with atorvastatin in patients with coronary heart disease (CHD) with and without preexisting chronic kidney disease (CKD). The study concluded that aggressive lipid lowering with atorvastatin 80 mg was both safe and effective in reducing excess cardiovascular events in a high-risk population with CKD and CHD [124] .
In patients with diabetes and class III-IV heart failure, initiation of statin therapy is not recommended because there is no clear evidence of benefit in this group. [III, A]
Summary of evidence
• The effect of rosuvastatin in patients with chronic heart failure (GISSI-HF) randomized, multicenter clinical trial evaluated rosuvastatin 10 mg/day compared to placebo in 2285 patients with heart failure due to any cause or condition (New York Heart Association classes II-IV); 26% also had diabetes. There was no benefit in the outcomes of interest (death and hospitalization for cardiovascular causes) [125] .
• The controlled rosuvastatin multinational trial in heart failure (CORONA) randomized study compared the use of rosuvastatin 10 mg versus placebo in 5011 patients aged >60 years with class II-IV heart failure of ischemic etiology (including 29% with diabetes). The primary endpoint was a composite of cardiovascular death, acute nonfatal MI, and nonfatal stroke during 36 months. Despite a 45% reduction in LDL-c, there was no significant between-group difference in the primary endpoint. The results were extensive to patients with diabetes in the subgroup analysis, due to low heterogeneity [126] .
• A retrospective analysis of the CORONA trial compared 10 mg rosuvastatin daily with placebo in patients with ischemic systolic heart failure according to baseline high sensitivity-C reactive protein (hs-CRP) <2.0 mg/L (placebo, n = 779; rosuvastatin, n = 777) or ≥2.0 mg/L (placebo, n = 1694; rosuvastatin, n = 1711). The primary outcome was cardiovascular death, myocardial infarction, or stroke. The study demonstrated a significant interaction between hs-CRP and the effect of rosuvastatin for most endpoints, whereby rosuvastatin treatment was associated with better outcomes in patients with hs-CRP ≥ 2.0 mg/L [127] . In addition, patients with heart failure due to ischemic heart disease who had NT-proBNP values <103 pmol/L (868 pg/mL) had the best prognosis and, if assigned to rosuvastatin rather than placebo, had a greater reduction in the primary endpoint (HR 0.65, 95% CI 0.47-0.88) than patients in the other tertiles (heterogeneity test, p = 0.0192). This reflected fewer atherothrombotic events and sudden deaths in the active group, and may show a benefit from rosuvastatin use [128] . • The pre-specified subgroup analysis of patients with diabetes from the ACCORD-LIPID (action to control cardiovascular risk in diabetes-lipids arm) study [129] , comparing micronized fenofibrate 160 mg plus simvastatin 20-40 mg versus simvastatin 20-40 mg alone plus fenofibrate placebo, showed no reduction in the primary outcome. However, there was benefit in the pre-specified subgroup analysis of patients with triglycerides >204 mg/dL and HDL-c < 34 mg/ dL.
• The FIELD (fenofibrate intervention and event lowering in diabetes) multinational RCT, randomized 9795 individuals with type 2 diabetes mellitus (aged 50-75 years, 2131 with previous cardiovascular disease and 7664 without) not on statin treatment at study enrollment to receive micronized fenofibrate 200 mg daily (n = 4895) or matching placebo (n = 4900) for 5 years of follow up. The primary outcome was coronary heart disease death or nonfatal myocardial infarction. The pre-specified outcome for subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization). Fenofibrate did not reduce risk of the primary outcome. However, it reduced the secondary pre-specified outcome of total cardiovascular events, due to fewer nonfatal myocardial infarctions and revascularizations [130] . • The ACCORD BP study used a 2 × 2 factorial design, which also included comparisons of standard or intensive glycemic targets combined with intensive or standard blood pressure control in the same trial. A secondary pre-specified analysis [132] showed that, when combining intensive glycemic control with intensive blood pressure control, the rate of major CVD outcomes was significantly lowered when compared with combined standard BP and standard glycemic control.
Module 6. Management of hypertension
• In a network meta-analysis including 42 clinical trials with random allocation into anti-hypertensive medication, control, or treatment target, a total of 144,220 individuals were compared in different strata of systolic blood pressure (SBP) to define the best target to reduce cardiovascular disease and all-cause mortality. The study concluded that, in patients with hypertension and coronary artery disease from routine clinical practice, SBP < 120 mmHg and DBP < 70 mmHg were each associated with adverse cardiovascular outcomes, including mortality, supporting the existence of a J-curve phenomenon. Thus, caution is advised in the use of antihypertensive treatment in patients with coronary artery disease [135] .
• The ARIC (Atherosclerosis Risk In Communities) cohort of 11,565 adults analyzed associations between DBP and high-sensitivity cardiac troponin T (hs-cTnT) levels, as well as prospective associations between DBP and CV events. Compared with persons who had DBP 80-89 mmHg at baseline (ARIC visit 2), the adjusted odds ratio of having hs-cTnT ≥ 14 ng/L at that visit was 2.2 and 1.5 in those with DBP < 60 mmHg and 60-69 mmHg, respectively. Low DBP at baseline was also independently associated with progressive myocardial damage on the basis of estimated annual change in hs-cTnT over the 6 years between ARIC visits 2 and 4. In addition, compared with a DBP of 80-89 mm Hg, a DBP < 60 mmHg was associated with incident CHD and mortality, but not with stroke. The DBP and incident CHD association was strongest with baseline hs-cTnT ≥ 14 ng/L (p value for interaction <0.001). Associations of low DBP with prevalent hs-cTnT and incident CHD were most pronounced among patients with baseline SBP ≥ 120 mmHg. The study concluded that, among adults with an SBP ≥ 120 mmHg (and, thus, elevated pulse pressure), low DBP was associated with subclinical myocardial damage and CHD events. When titrating treatment to SBP < 140 mmHg, it may be prudent to ensure that DBP levels do not fall below 70 mmHg and, particularly, not below 60 mmHg [136] .
In patients with diabetes aged 80 years or older, a systolic blood pressure target <150 mmHg is reasonable. [IIa, B]
Summary of evidence
• In the hypertensive elderly (age ≥ 80 years), there is no evidence of benefits deriving from BP levels <140 mmHg, but there is an increased likelihood of adverse effects. The HYVET Study supports the recommendation of a BP target <150/90 mmHg, with a reduction in the risk of stroke and HF [137, 138] . The presence of isolated systolic hypertension (ISH) requires care regarding excessive reduction in DBP, which should be maintained over 60 mmHg or even over 65 mmHg in the presence of CAD [139] .
• The SPRINT study reported a 24% reduction in the risk of the study's primary outcome in elderly patients (age ≥75 years) allocated to the more intense BP treatment arm (mean SBP achieved, 123.4 mmHg) as compared to the group of standard SBP reduction (mean BP achieved, 134.8 mmHg). This occurred regardless of degree of fragility, with no increase in the number of adverse events in relation to the rest of the study population [140] . That suggests that BP targets for the elderly should be defined in the same as for other adults. It should be noted, however, that BP reduction should be performed carefully, considering comorbidities and the use of multiple medications. • In the IRMA-2 multinational, double-blind RCT, 590 hypertensive patients with type 2 diabetes and microalbuminuria were enrolled to receive irbesartan 150 mg daily or 300 mg daily for 2 years. The primary outcome was time to onset of diabetic nephropathy, defined by persistent albuminuria in overnight specimens, with a urinary albumin excretion rate >200 mcg/min and at least 30% higher than the • The randomized, double-blind, active-controlled antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), conducted from February 1994 through March 2002, evaluated 33,357 participants (age ≥ 55 years) with hypertension and at least one additional CHD risk factor from 623 North American centers to determine if calcium channel blockers or angiotensin-converting enzyme (ACE) inhibitors would lower the incidence of CHD or other CV events vs. treatment with a diuretic. The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intention to treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure, and peripheral arterial disease). The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlortalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. For amlodipine vs. chlortalidone, secondary outcomes were similar except for a higher 6-year rate of heart failure with amlodipine (10.2% vs. [144] .
• An analysis of the ALLHAT study to determine if treatment with a calcium channel blocker or an ACE inhibitor would decrease clinical complications compared with treatment with a thiazide-type diuretic in DM, IFG, and normoglycemia provided no evidence of superiority for treatment with calcium channel blockers or ACE inhibitors compared with a thiazide-type diuretic during first-step antihypertensive therapy in these populations [145] .
• A meta-analysis of 354 randomized, double-blind, placebo-controlled trials of thiazides, beta blockers, ACE inhibitors, angiotensin II receptor antagonists, and calcium channel blockers in fixed dose was performed. Placebo adjusted reductions in systolic and diastolic blood pressure and prevalence of adverse effects, according to dose expressed as a multiple of the standard (recommended) doses of the drugs, were the main outcomes. All five classes produced similar reductions in blood pressure, with average SBP and DBP reductions of 9.1 and 5.5 mmHg respectively at standard doses and 7.1 and 4.4 mmHg respectively (20% lower) at half-standard doses. The drugs reduced blood pressure from all pretreatment levels, more so from higher levels; for a 10 mmHghigher blood pressure, the reduction was 1.0 mmHg greater in SBP and 1.1 mmHg greater in DBP. The BP-lowering effects of different drug classes were additive. In addition, combination low-dose treatment increased efficacy and reduced adverse effects. From the average blood pressure in people who have strokes (150/90 mmHg), three drugs at half-standard dose were estimated to lower blood pressure by 20 mmHg systolic and 11 mmHg diastolic, thereby reducing the risk of stroke by 63% and the risk of ischemic heart disease events by 46% in the 60-69 age range [146] .
In patients with diabetes and urinary albumin >30 mg/g, treatment with ACE inhibitors or angiotensin receptor blockers are indicated. [I, A]
Summary of evidence
• The reduction in end points in noninsulin-dependent diabetes mellitus with the angiotensin II antagonist losartan (RENAAL) study [147] investigated if albuminuria, a marker of renal disease, could also be a monitor of the renoprotective efficacy of RAS intervention by the angiotensin II (Ang II) antagonist losartan in patients with diabetic nephropathy. Data from the a double-blind randomized RENAAL trial were used to examine the effects of losartan on a renal outcome (primary composite endpoint of doubling of serum creatinine, end-stage renal disease, or death) in 1513 type 2 diabetic patients with nephropathy. The effect of the degree of albuminuria at baseline, initial antiproteinuric response to therapy, and the degree of residual albuminuria on renal outcome (either the primary composite end point of RENAAL or ESRD) were examined, as well as the contribution to renal protection of the antiproteinuric effect of losartan independently of changes in blood pressure. Albuminuria was the predominant renal risk marker in patients with type 2 diabetic nephropathy on conventional treatment; the higher the albuminuria, the greater the renal risk. Reduction in albuminuria was associated with a proportional effect on renal protection; the greater the reduction, the greater the renal protection. Residual albuminuria while on therapy (month 6) was considered as a strong marker of renal outcome, as was baseline albuminuria. The antiproteinuric effect of losartan explained a major component of its specific renoprotective effect. Reduction of residual albuminuria to the lowest achievable level should be viewed as a goal for renoprotective treatments.
• The Irbesartan Diabetic Nephropathy Trial addressed whether associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure would be related to the cumulative incidence of renal endpoints. The risk of kidney failure doubled for each doubling of baseline proteinuria level (HR 2.04, 95% CI 1.87-2.22, p < 0.001). For each halving of proteinuria level between baseline and 12 months on treatment, risk of kidney failure was reduced by more than half (HR 0.44, 95% CI 0.40-0.49, p < 0.001). The reduction in risk for kidney failure was significantly greater for irbesartan vs. amlodipine (p = 0.048), but not control (p = 0.245) for the same proportional change in proteinuria. Proteinuria reduction in the first 12 months of therapy with irbesartan was associated with 36% of the total renoprotective effect observed. Proteinuria reduction using an angiotensin receptor-blocking agent should be regarded as an important therapeutic goal for renoprotection [148] .
• The MICRO-HOPE study investigated whether the ACE inhibitor ramipril could lower risk of cardiovascular and renal disease in patients with diabetes [149] . A subset of 3577 people with diabetes included in the Heart Outcomes Prevention Evaluation study, aged 55 years or older, with a previous cardiovascular event or at least one other cardiovascular risk factor, no clinical proteinuria, heart failure, or low ejection fraction, and who were not taking ACE inhibitors were randomly assigned to receive ramipril (10 mg/ day) or placebo and vitamin E or placebo, according to a two-by-two factorial design. The combined primary outcome was myocardial infarction, stroke, or CV death. Overt nephropathy was a main outcome in a substudy. The study was interrupted 6 months earlier (after 4.5 years) because of a consistent benefit of ramipril compared with placebo. Ramipril lowered the risk of the combined primary outcome by 25% (95% CI 12-36, p = 0.0004), myocardial infarction by 22% (95% CI 6-36), stroke by 33% (95% CI 10-50), CV death by 37% (95% CI 21-51), total mortality by 24% (95% CI 8-37), revascularization by 17% (95% CI 2-30), and overt nephropathy by 24% (95% CI 3-40, p = 0.027).
After adjustment for changes in SBP (2.4 mmHg) and DBP (1.0 mmHg), ramipril still lowered the risk of the combined primary outcome by 25% (95% CI 12-36, p = 0.0004). Ramipril was beneficial for cardiovascular events and overt nephropathy in people with diabetes. The study concluded that cardiovascular benefit was greater than that attributable to the decrease in blood pressure, thus representing a vasculoprotective and renoprotective effect for people with diabetes.
51. When using more than one antihypertensive to achieve target blood pressure, it is reasonable to combine either an ACE inhibitor or an ARB with a dihydropyridine calcium channel blocker. [IIa, B] Summary of evidence
• The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension) substudy [150] , was designed to determine which combination therapy in patients with hypertension and diabetes most effectively decreased cardiovascular events. The outcomes effects of the ACE inhibitor benazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H), were analyzed separately in diabetic patients as a pre-specified endpoint. A total of 6946 patients with diabetes were randomized to treatment with B+A or B+H. A subgroup of 2842 diabetic patients at very high risk (previous CV events or stroke) was also analyzed, as were 4559 patients without diabetes. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitated arrest, and coronary revascularization. In the full diabetes group, the mean achieved blood pressures in the B+A and B+H groups were 131. The rates of hyperkalemia, hypotension, and renal impairment/failure were higher in the aliskiren group than in the placebo arm. Among patients hospitalized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce CV death or HF readmission at 6 months or 12 months after discharge.
• In patients who have vascular disease or high-risk diabetes without heart failure, ACE inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of ARBs in such patients is unknown. The ACE inhibitor ramipril, the ARB telmisartan, and a combination of the two drugs in patients with vascular disease or high-risk diabetes were compared in the ONTARGET study [154] . A total of 8576 patients were assigned to receive 10 mg of ramipril per day, 8542 were assigned to receive 80 mg of telmisartan per day, and 8502 were assigned to receive both drugs. The primary composite outcome (death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure) occurred in 16.5% of patients in the ramipril group, 16.7% in the telmisartan group, and 16.3% in the combined-therapy group (differences were not statistically significant). However, more adverse events were seen in patients randomized to combined therapy. In conclusion, the combination of the two drugs was associated with more adverse events, without increased benefit. • Trials of antiplatelet therapy versus control included about 70,000 "high-risk" patients (with vascular disease or another condition implying an increased risk of occlusive vascular disease) and 30,000 "low-risk" subjects from the general population. Direct comparisons of different antiplatelet regimens involved about 10,000 high-risk patients. In each of four main high-risk categories, antiplatelet therapy was definitely protective. Among low-risk recipients of "primary prevention", a significant, one-third reduction in nonfatal myocardial infarction was accompanied by a nonsignificant increase in stroke. The absolute reduction in vascular events was much smaller than for high-risk patients, despite a much longer treatment period, and was not significant. There is no clear evidence on the balance of antiplatelet therapy in primary prevention among low-risk subjects [155] .
• A meta-analysis of randomized controlled trials was performed to evaluate the benefits and harms of lowdose aspirin in people with diabetes and no cardiovascular disease. Six studies were eligible, with 10,117 participants. When aspirin was compared with placebo, there was no statistically significant reduction in the risk of major CV events (five studies, n = 9584; RR 0.90, 95% CI 0. • The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial was designed to examine the efficacy of low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes and no previous cardiovascular events. The study randomized 1262 patients to receive aspirin (81 mg or 100 mg) and 1277 patients to a nonaspirin group. Mean (SD) age was 65 (10) years, and 55% were men; 58% of patients had hypertension, 53% had dyslipidemia, and BP and HbA1c were well controlled in both groups. The median follow-up period was 4.37 years and 193 patients were lost to follow-up, with data for those patients censored at the day of last follow-up. There was no reduction in the risk of CV events with low-dose aspirin for high-risk patients with diabetes in primary prevention. However, the event rate was lower than expected overall, and these findings should be interpreted in context with the low incidence of atherosclerotic disease in Japan and current management of cardiovascular risk factors [157] .
• A sub-analysis from the JPAD study evaluating patients with diabetes divided according to SBP and DBP at enrollment ("target unattained" group, SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg; "target attained" group, SBP < 140 mmHg and DBP < 90 mmHg) demonstrated that the incidence of the primary atherosclerotic events, especially cerebrovascular events, was higher in the unattained group than in the attained group. The incidence of cerebrovascular events was higher in the unattained group than in the attained group in patients without aspirin therapy; however, the incidence of cerebrovascular events in the unattained group was as low as the incidence in the attained group in patients on aspirin therapy. Cox proportional hazards analysis revealed that BP level was an independent predictor of cerebrovascular events in diabetic patients [158] . Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes [164] .
• In the multicenter, double-blind, randomized PLATO trial, ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-600-mg loading dose, 75 mg daily thereafter) were compared for the prevention of CV events in 18,624 patients admitted to hospital with an acute coronary syndrome, with or without ST-segment elevation. At 12 months, the primary composite endpoint (death from vascular causes, myocardial infarction, or stroke) had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (p < 0.001). The rate of death from any cause was also reduced with ticagrelor (4.5% vs. 5.9% with clopidogrel, p < 0.001). No significant difference in rates of major bleeding was found between the ticagrelor and clopidogrel groups (p = 0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, p = 0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types [165] .
• The PEGASUS study investigated the efficacy and safety of ticagrelor after an acute coronary syndrome, in a double-blind 1:1:1 fashion. The trial randomized 21,162 patients who had had a myocardial infarction 1-3 years earlier to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo. All patients received low-dose aspirin and were followed for a median of 33 months. The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction, or stroke. • In the PEGASUS study, the efficacy and safety of ticagrelor after an acute coronary syndrome was investigated in a double-blind 1:1:1 fashion. The trial randomized 21,162 patients who had had a myocardial infarction 1-3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients received low-dose aspirin and were followed for a median of 33 months. The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. Ticagrelor in both doses reduced the rate of the primary efficacy endpoint, with Kaplan-Meier rates at 3 years of 7.85% in the group receiving 90 mg of ticagrelor twice daily, 7.77% in the group receiving 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% CI 0.75-0.96; p = 0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI 0.74-0.95; p = 0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (p < 0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63, 0.71, and 0.60% respectively. Therefore, in patients with a previous myocardial infarction, at least one year earlier, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke, and increased the risk of major bleeding [166] . The DAPT study sought to investigate if 30 months of DAPT was superior to 12 months in patients undergoing DES and baremetal stent (BMS) PCI. A total of 9961 patients were randomized at 452 sites in 11 countries: 5020 to prolonged DAPT and 4941 to placebo. Approximately 30% had diabetes mellitus, 25% were smokers and 6% had peripheral arterial disease. Patients were enrolled 72 h after stent placement and were given openlabel aspirin and thienopyridine for 12 months, per current practice norms. Indication for PCI was stable angina in 38%, ST-segment elevation myocardial infarction (STEMI) in 10% and NSTE-acute coronary syndrome (NSTE-ACS) in 32%. Approximately twothirds of the patients received clopidogrel, whereas the rest received prasugrel. At 12 months, patients without an ischemic or bleeding complication and with documented compliance, were randomized in a 1:1 fashion to receive an additional 18 months of DAPT or matching placebo. The primary endpoint of major adverse cardiac and cerebrovascular events (MACCE) was significantly lower in the continued DAPT arm compared with placebo (4.3% vs. 5.9%, hazard ratio 0.71, 95% confidence interval 0.59-0.85, p < 0.001). There were reductions in all MI (2.1% vs. 4.1%, p < 0.001) and stent thrombosis (0.4% vs. 1.4%, p < 0.001), but all-cause mortality was higher (2.0% vs. 1.5%, p = 0.05), driven mostly by an increase in non-cardiovascular deaths (1% vs. 0.5%, p = 0.002), including cancer-related death (0.62% vs. 0.28%, p = 0.02) and bleeding-related death (0.22% vs. 0.06%, p = 0.06). Moderate and severe GUSTO bleeding was also higher with DAPT (2.5% vs. 1.6%, p = 0.001), as was BARC 2, 3, or, 5 bleeding (5.6% vs. 2.9%, p < 0.001). The DAPT study showed that longer duration of DAPT following PCI results in lower stent thrombosis and recurrent MIs, but higher bleeding and all-cause mortality compared with a 12-month duration [167] .
Conclusions
Although cardiovascular risk is increased in patients with diabetes when compared to age-matched nondiabetic individuals, recent evidence indicates that there is a high prevalence of lower-risk individuals among this population. Risk stratification is clearly needed, either to intensify more effective preventive measures in highrisk categories or to avoid overtreatment of lower-risk patients. The present Panel structured a risk-based guide to help clinicians optimize cardiovascular prevention in diabetes. The Panel recovered the concept of treating-totarget, as they are considered important to promote better adhesion to treatment and can be useful for clinicians to improve prevention in clinical practice. In the present guideline, there is a clear shift toward a more intensive treatment in the very-high risk category, especially regarding lipid-lowering therapy with statins, where new, lower lipid targets are proposed. The Panel understands that patients with diabetes at very high risk have very high mortality and one of the most important currently available actions to reduce residual risk is to obtain further reductions in LDL-c levels. The panel also reviews the potential role of the new anti-hyperglycemic drugs in reducing cardiovascular risk, as well as hypertension targets and drug choice. Finally, we also propose a practical guideline to guide decision-making about screening for silent coronary artery disease. We understand that intensifying treatment may increase costs to the health care system; however, the number of avoided events and lives saved clearly outweighs these costs. The Brazilian Diabetes Society, the Brazilian Cardiology Society, and the Brazilian Endocrinology Society are now united in the task to reduce cardiovascular disease in patients with diabetes. 
